Fab’entech’s platform is used for the development and manufacturing of immunotherapies composed of highly purified F(ab’)2 fragments of horse specific polyclonal immunoglobulins.
This technology has been developed by Sanofi Pasteur, then in-licensed by Fab'entech. Such platform having been fully-validated with the development of Fabenflu®, Fab’entech can develop and manufacture, in a short period of time and for limited investments, new immunotherapies from high quality & security standards.
Fab'entech's manufacturing activities are currently performed in the R&D laboratory located in its principal office in Lyon.
However, in order to align its industrial capacity with its R&D pipeline, Fab'entech is also building an industrial manufacturing site based on a modular system, which is located only 15 minutes away from its Lyon office, and with which it will be able to produce clinical batches at short-term and commercial batches at mid-term.
- Herbreteau CH, Denizot M, Lowther S, Riddell S, Frazer L, Haining J, Arkinstall R, Payne J, Harper J, et al. (2016). Efficacy of specific polyclonal equine F(ab')2 against avian influenza (H5N1) in ferrets: synergy with oseltamivir. Immunotherapy 8(9), 1021-1032.
- Bal C, Herbreteau CH, Buchy P, Rith S, Zaid M, Kristanto W, Han V, Reynaud C, Granjard P, Lepine B, et al. (2015). Safety, potential efficacy, and pharmacokinetics of specific polyclonal immunoglobulin F(ab’)2 fragments against avian influenza A (H5N1) in healthy volunteers: a single-centre, randomised, double-blind, placebo-controlled, phase 1 study. Lancet Infect Dis 15, 285-292.
- Herbreteau CH, Jacquot F, Rith S, Vacher L, Nguyen L, Carbonnelle C, Lotteau V, Jolivet M, Raoul H, Buchy P, et al. (2014). Specific polyclonal F(ab’) neutralize a large panel of highly pathogenic avian influenza A viruses (H5N1) and control infection in mice. Immunotherapy.
- Nguyen L. Production d’immunoglobulines thérapeutiques hautement purifiées (ITHP) : analyse d’un procédé de purification. Biologie Aujourd’hui 204, 55–59 (2010).